Safety of ultra-rapid intravenous infusion of hepatitis B immunoglobulin in liver transplant recipients

S. Hwang; Y. D. Yu; G. C. Park; Y. I. Choi; P. J. Park; S. W. Jung; J. M. Namgoong; S. Y. Yoon; H. S. Ha; J. J. Hong; I. O. Kim; M. K. Jeon; J. E. Ma; S. Y. Choi; J. S. Yun; D. H. Jung; G. W. Song; T. Y. Ha; D. B. Moon; K. H. Kimy; C. S. Ahn; S. G. Lee

doi:10.1016/j.transproceed.2011.02.013

Safety of ultra-rapid intravenous infusion of hepatitis B immunoglobulin in liver transplant recipients

S. Hwang, Y. D. Yu, G. C. Park, Y. I. Choi, P. J. Park, S. W. Jung, J. M. Namgoong, S. Y. Yoon, H. S. Ha, J. J. Hong, I. O. Kim, M. K. Jeon, J. E. Ma, S. Y. Choi, J. S. Yun, D. H. Jung, G. W. Song, T. Y. Ha, D. B. Moon, K. H. KimyC. S. Ahn, S. G. Lee

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Purpose: To evaluate the safety of institutional protocol for ultra-rapid hepatitis B immunoglobulin (HBIG) infusion (10,000 IU in 30 minutes) for hepatitis B virus prophylaxis in adult liver transplant recipients. Methods: In this case-controlled study, prospectively recruited liver transplant recipients received ultra-rapid infusions of HBIG (10,000 units in 30 minutes) for 6 months. The historical control group consisted of patients who had received 1-hour HBIG infusions (conventional rapid infusion) for the precedent 6 months. Results: We found that 1472 patients had received 5744 ultra-rapid HBIG infusions, whereas 1343 patients had received 5200 conventional rapid HBIG infusions. Adverse side-effects were observed after 7 (0.13%) and 9 (0.16%) infusions, respectively (P = .763). The number of infusions per month increased significantly, from 878 ± 34 before the introduction of ultra-rapid infusion to 957 ± 29 afterwards (P < .001), an increase of 10.5%. The maximal capacity of HBIG infusions per day in the outpatient clinic increased from 53 for conventional rapid infusion to 65 for ultra-rapid infusion, without expansion of the outpatient facility or equipment. Conclusions: Nearly all adult liver recipients able to tolerate 1-hour infusions of HBIG can also tolerate ultra-rapid infusions well. Thus, it seems to be reasonable to perform ultra-rapid infusion protocol widely for patient convenience.

Original language	English
Pages (from-to)	1780-1782
Number of pages	3
Journal	Transplantation Proceedings
Volume	43
Issue number	5
DOIs	https://doi.org/10.1016/j.transproceed.2011.02.013
Publication status	Published - 2011 Jun
Externally published	Yes

ASJC Scopus subject areas

Surgery
Transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.transproceed.2011.02.013

Cite this

Hwang, S., Yu, Y. D., Park, G. C., Choi, Y. I., Park, P. J., Jung, S. W., Namgoong, J. M., Yoon, S. Y., Ha, H. S., Hong, J. J., Kim, I. O., Jeon, M. K., Ma, J. E., Choi, S. Y., Yun, J. S., Jung, D. H., Song, G. W., Ha, T. Y., Moon, D. B., ... Lee, S. G. (2011). Safety of ultra-rapid intravenous infusion of hepatitis B immunoglobulin in liver transplant recipients. Transplantation Proceedings, 43(5), 1780-1782. https://doi.org/10.1016/j.transproceed.2011.02.013

Hwang, S, Yu, YD, Park, GC, Choi, YI, Park, PJ, Jung, SW, Namgoong, JM, Yoon, SY, Ha, HS, Hong, JJ, Kim, IO, Jeon, MK, Ma, JE, Choi, SY, Yun, JS, Jung, DH, Song, GW, Ha, TY, Moon, DB, Kimy, KH, Ahn, CS & Lee, SG 2011, 'Safety of ultra-rapid intravenous infusion of hepatitis B immunoglobulin in liver transplant recipients', Transplantation Proceedings, vol. 43, no. 5, pp. 1780-1782. https://doi.org/10.1016/j.transproceed.2011.02.013

@article{fe48f89ecdf849019dd758240fe990d7,

title = "Safety of ultra-rapid intravenous infusion of hepatitis B immunoglobulin in liver transplant recipients",

abstract = "Purpose: To evaluate the safety of institutional protocol for ultra-rapid hepatitis B immunoglobulin (HBIG) infusion (10,000 IU in 30 minutes) for hepatitis B virus prophylaxis in adult liver transplant recipients. Methods: In this case-controlled study, prospectively recruited liver transplant recipients received ultra-rapid infusions of HBIG (10,000 units in 30 minutes) for 6 months. The historical control group consisted of patients who had received 1-hour HBIG infusions (conventional rapid infusion) for the precedent 6 months. Results: We found that 1472 patients had received 5744 ultra-rapid HBIG infusions, whereas 1343 patients had received 5200 conventional rapid HBIG infusions. Adverse side-effects were observed after 7 (0.13%) and 9 (0.16%) infusions, respectively (P = .763). The number of infusions per month increased significantly, from 878 ± 34 before the introduction of ultra-rapid infusion to 957 ± 29 afterwards (P < .001), an increase of 10.5%. The maximal capacity of HBIG infusions per day in the outpatient clinic increased from 53 for conventional rapid infusion to 65 for ultra-rapid infusion, without expansion of the outpatient facility or equipment. Conclusions: Nearly all adult liver recipients able to tolerate 1-hour infusions of HBIG can also tolerate ultra-rapid infusions well. Thus, it seems to be reasonable to perform ultra-rapid infusion protocol widely for patient convenience.",

author = "S. Hwang and Yu, {Y. D.} and Park, {G. C.} and Choi, {Y. I.} and Park, {P. J.} and Jung, {S. W.} and Namgoong, {J. M.} and Yoon, {S. Y.} and Ha, {H. S.} and Hong, {J. J.} and Kim, {I. O.} and Jeon, {M. K.} and Ma, {J. E.} and Choi, {S. Y.} and Yun, {J. S.} and Jung, {D. H.} and Song, {G. W.} and Ha, {T. Y.} and Moon, {D. B.} and Kimy, {K. H.} and Ahn, {C. S.} and Lee, {S. G.}",

year = "2011",

month = jun,

doi = "10.1016/j.transproceed.2011.02.013",

language = "English",

volume = "43",

pages = "1780--1782",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier USA",

number = "5",

}

TY - JOUR

T1 - Safety of ultra-rapid intravenous infusion of hepatitis B immunoglobulin in liver transplant recipients

AU - Hwang, S.

AU - Yu, Y. D.

AU - Park, G. C.

AU - Choi, Y. I.

AU - Park, P. J.

AU - Jung, S. W.

AU - Namgoong, J. M.

AU - Yoon, S. Y.

AU - Ha, H. S.

AU - Hong, J. J.

AU - Kim, I. O.

AU - Jeon, M. K.

AU - Ma, J. E.

AU - Choi, S. Y.

AU - Yun, J. S.

AU - Jung, D. H.

AU - Song, G. W.

AU - Ha, T. Y.

AU - Moon, D. B.

AU - Kimy, K. H.

AU - Ahn, C. S.

AU - Lee, S. G.

PY - 2011/6

Y1 - 2011/6

N2 - Purpose: To evaluate the safety of institutional protocol for ultra-rapid hepatitis B immunoglobulin (HBIG) infusion (10,000 IU in 30 minutes) for hepatitis B virus prophylaxis in adult liver transplant recipients. Methods: In this case-controlled study, prospectively recruited liver transplant recipients received ultra-rapid infusions of HBIG (10,000 units in 30 minutes) for 6 months. The historical control group consisted of patients who had received 1-hour HBIG infusions (conventional rapid infusion) for the precedent 6 months. Results: We found that 1472 patients had received 5744 ultra-rapid HBIG infusions, whereas 1343 patients had received 5200 conventional rapid HBIG infusions. Adverse side-effects were observed after 7 (0.13%) and 9 (0.16%) infusions, respectively (P = .763). The number of infusions per month increased significantly, from 878 ± 34 before the introduction of ultra-rapid infusion to 957 ± 29 afterwards (P < .001), an increase of 10.5%. The maximal capacity of HBIG infusions per day in the outpatient clinic increased from 53 for conventional rapid infusion to 65 for ultra-rapid infusion, without expansion of the outpatient facility or equipment. Conclusions: Nearly all adult liver recipients able to tolerate 1-hour infusions of HBIG can also tolerate ultra-rapid infusions well. Thus, it seems to be reasonable to perform ultra-rapid infusion protocol widely for patient convenience.

AB - Purpose: To evaluate the safety of institutional protocol for ultra-rapid hepatitis B immunoglobulin (HBIG) infusion (10,000 IU in 30 minutes) for hepatitis B virus prophylaxis in adult liver transplant recipients. Methods: In this case-controlled study, prospectively recruited liver transplant recipients received ultra-rapid infusions of HBIG (10,000 units in 30 minutes) for 6 months. The historical control group consisted of patients who had received 1-hour HBIG infusions (conventional rapid infusion) for the precedent 6 months. Results: We found that 1472 patients had received 5744 ultra-rapid HBIG infusions, whereas 1343 patients had received 5200 conventional rapid HBIG infusions. Adverse side-effects were observed after 7 (0.13%) and 9 (0.16%) infusions, respectively (P = .763). The number of infusions per month increased significantly, from 878 ± 34 before the introduction of ultra-rapid infusion to 957 ± 29 afterwards (P < .001), an increase of 10.5%. The maximal capacity of HBIG infusions per day in the outpatient clinic increased from 53 for conventional rapid infusion to 65 for ultra-rapid infusion, without expansion of the outpatient facility or equipment. Conclusions: Nearly all adult liver recipients able to tolerate 1-hour infusions of HBIG can also tolerate ultra-rapid infusions well. Thus, it seems to be reasonable to perform ultra-rapid infusion protocol widely for patient convenience.

UR - http://www.scopus.com/inward/record.url?scp=79959483531&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.02.013

DO - 10.1016/j.transproceed.2011.02.013

M3 - Article

C2 - 21693278

AN - SCOPUS:79959483531

SN - 0041-1345

VL - 43

SP - 1780

EP - 1782

JO - Transplantation Proceedings

JF - Transplantation Proceedings

IS - 5

ER -

Safety of ultra-rapid intravenous infusion of hepatitis B immunoglobulin in liver transplant recipients

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this